Country: Switzerland
Sector: Health Care
Website: http://www.novartis.comNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
3.30% (5y avg: 3.64%)
3.99 USD
March 12, 2025
60.27%
Year | Total Dividends |
---|---|
2026 | 7.54 USD |
April 21, 2026 (estimated) | 3.9940 |
March 31, 2026 (estimated) | 3.5415 |
2025 | 14.33 USD |
Sept. 24, 2025 (estimated) | 3.7772 |
April 25, 2025 | 3.9940 |
March 31, 2025 | 3.2771 |
March 27, 2025 | 3.2771 |
2024 | 7.55 USD |
Sept. 24, 2024 | 3.7772 |
April 19, 2024 | 3.7772 |
2023 | 3.47 USD |
March 20, 2023 | 3.4694 |
2022 | 3.36 USD |
March 17, 2022 | 3.3570 |
2021 | 3.38 USD |
March 15, 2021 | 3.3784 |
2020 | 3.04 USD |
March 12, 2020 | 3.0420 |
2019 | 2.57 USD |
March 13, 2019 | 2.5672 |
2018 | 2.67 USD |
April 25, 2018 | 2.6676 |
2017 | 2.46 USD |
April 20, 2017 | 2.4606 |
2016 | 2.47 USD |
April 15, 2016 | 2.4749 |
2015 | 2.52 USD |
April 20, 2015 | 2.5242 |
2014 | 2.44 USD |
April 10, 2014 | 2.4364 |
2013 | 2.27 USD |
April 5, 2013 | 2.2670 |
2012 | 2.20 USD |
April 5, 2012 | 2.2043 |
2011 | 2.11 USD |
April 8, 2011 | 2.1084 |
2010 | 1.78 USD |
March 2, 2010 | 1.7805 |
2009 | 1.54 USD |
Feb. 24, 2009 | 1.5412 |
2008 | 1.32 USD |
Feb. 26, 2008 | 1.3190 |
2007 | 0.97 USD |
March 6, 2007 | 0.9686 |
2006 | 0.80 USD |
Feb. 28, 2006 | 0.8011 |
2005 | 0.86 USD |
March 1, 2005 | 0.8635 |
2004 | 0.72 USD |
Feb. 24, 2004 | 0.7222 |
2003 | 0.63 USD |
March 4, 2003 | 0.6272 |
2002 | 0.47 USD |
March 21, 2002 | 0.4677 |
2001 | 0.45 USD |
March 22, 2001 | 0.4498 |
2000 | 1.37 USD |
Nov. 14, 2000 | 0.9660 |
April 12, 2000 | 0.4012 |
1999 | 0.48 USD |
April 21, 1999 | 0.4763 |
1998 | 0.42 USD |
April 21, 1998 | 0.4182 |
1997 | 0.34 USD |
April 16, 1997 | 0.3403 |
Yearly aggregated dividends
Novartis AG
Mar 31, 2025 Paid
Dividend
3.2771 USD |
Novartis AG
Mar 27, 2025 Paid
Dividend
3.2771 USD |
Novartis AG
Apr 25, 2025 Paid
Dividend
3.994 USD |
Novartis AG
Sep 24, 2024 Paid
Dividend
3.7772 USD |
Split Date | Split Ratio to 1 |
---|---|
May 11, 2000 | 2.00 |
April 9, 2019 | 1.12 |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion